AvenCell Therapeutics Announces First Patient Dosed in Phase I QUADvance Study with AVC-203, a Novel Allogeneic CD19/CD20 Dual-Targeting CAR-T Investigational Therapy for the Treatment of Relapsed/Refractory B-Cell Malignancies

AI Briefing

• – AvenCell Therapeutics announces Phase I trial of AVC-203, a CAR-T therapy for B-cell malignancies.
• – AVC-203 is the world's first CRISPR-engineered allogeneic dual-targeting CAR-T cell therapy.
• – First patient dosed in Phase I QUADvance Study with AVC-203 for treatment of relapsed/refractory B-cell malignancies.